163 related articles for article (PubMed ID: 10588099)
1. Unusual cervical spinal cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide in conjunction with osmotic blood brain-barrier disruption in the vertebral artery.
Fortin D; McAllister LD; Nesbit G; Doolittle ND; Miner M; Hanson EJ; Neuwelt EA
AJNR Am J Neuroradiol; 1999; 20(10):1794-802. PubMed ID: 10588099
[TBL] [Abstract][Full Text] [Related]
2. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
[TBL] [Abstract][Full Text] [Related]
3. Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
Newton HB; Stevens C; Santi M
J Neurooncol; 2001 Dec; 55(3):179-84. PubMed ID: 11859973
[TBL] [Abstract][Full Text] [Related]
4. Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
Guillaume DJ; Doolittle ND; Gahramanov S; Hedrick NA; Delashaw JB; Neuwelt EA
Neurosurgery; 2010 Jan; 66(1):48-58; discussion 58. PubMed ID: 20023537
[TBL] [Abstract][Full Text] [Related]
5. Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas.
Newton HB; Slivka MA; Stevens CL; Bourekas EC; Christoforidis GA; Baujan MA; Chakeres DW
J Neurooncol; 2002 Jan; 56(1):79-86. PubMed ID: 11949830
[TBL] [Abstract][Full Text] [Related]
6. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
Fortin D; Gendron C; Boudrias M; Garant MP
Cancer; 2007 Feb; 109(4):751-60. PubMed ID: 17211866
[TBL] [Abstract][Full Text] [Related]
7. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
[TBL] [Abstract][Full Text] [Related]
8. Combined intraarterial carboplatin, intraarterial etoposide phosphate, and IV Cytoxan chemotherapy for progressive optic-hypothalamic gliomas in young children.
Osztie E; Várallyay P; Doolittle ND; Lacy C; Jones G; Nickolson HS; Neuwelt EA
AJNR Am J Neuroradiol; 2001 May; 22(5):818-23. PubMed ID: 11337321
[TBL] [Abstract][Full Text] [Related]
9. Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors.
Newton HB; Slivka MA; Volpi C; Bourekas EC; Christoforidis GA; Baujan MA; Slone W; Chakeres DW
J Neurooncol; 2003 Jan; 61(1):35-44. PubMed ID: 12587794
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms.
Williams PC; Henner WD; Roman-Goldstein S; Dahlborg SA; Brummett RE; Tableman M; Dana BW; Neuwelt EA
Neurosurgery; 1995 Jul; 37(1):17-27; discussion 27-8. PubMed ID: 8587686
[TBL] [Abstract][Full Text] [Related]
11. [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
Yamada K; Takahama H; Nakai O; Takanashi T; Hosoya T
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2692-6. PubMed ID: 2506817
[TBL] [Abstract][Full Text] [Related]
12. MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy.
Roman-Goldstein S; Mitchell P; Crossen JR; Williams PC; Tindall A; Neuwelt EA
AJNR Am J Neuroradiol; 1995 Mar; 16(3):543-53. PubMed ID: 7793380
[TBL] [Abstract][Full Text] [Related]
13. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
[TBL] [Abstract][Full Text] [Related]
14. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
Hall WA; Doolittle ND; Daman M; Bruns PK; Muldoon L; Fortin D; Neuwelt EA
J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
[TBL] [Abstract][Full Text] [Related]
15. Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy.
Lauer AK; Wobig JL; Shults WT; Neuwelt EA; Wilson MW
Am J Ophthalmol; 1999 Feb; 127(2):230-3. PubMed ID: 10030580
[TBL] [Abstract][Full Text] [Related]
16. Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
Galor A; Ference SJ; Singh AD; Lee MS; Stevens GH; Perez VL; Peereboom DM
Am J Ophthalmol; 2007 Jul; 144(1):45-49. PubMed ID: 17601426
[TBL] [Abstract][Full Text] [Related]
17. A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue.
Shea TC; Storniolo AM; Mason JR; Newton B; Mullen M; Taetle R; Green MR
Semin Oncol; 1992 Feb; 19(1 Suppl 2):139-44. PubMed ID: 1411625
[TBL] [Abstract][Full Text] [Related]
18. Re: Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
Goldstein DA; Tessler HH
Am J Ophthalmol; 2007 Dec; 144(6):976; author reply 976. PubMed ID: 18036877
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma.
Neuwelt EA; Howieson J; Frenkel EP; Specht HD; Weigel R; Buchan CG; Hill SA
Neurosurgery; 1986 Oct; 19(4):573-82. PubMed ID: 3097567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
